Verastem Stock Price, News & Analysis (NASDAQ:VSTM) $6.78 +0.38 (+5.94%) (As of 03:15 PM ET) Add Compare Share Share Today's Range$6.45▼$6.8150-Day Range$6.05▼$9.7052-Week Range$3.87▼$15.18Volume69,448 shsAverage Volume163,105 shsMarket Capitalization$171.33 millionP/E RatioN/ADividend YieldN/APrice Target$29.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Verastem MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside342.8% Upside$29.71 Price TargetShort InterestHealthy2.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$7,565 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.67) to ($3.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.27 out of 5 starsMedical Sector285th out of 949 stocksPharmaceutical Preparations Industry121st out of 441 stocks 3.5 Analyst's Opinion Consensus RatingVerastem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.71, Verastem has a forecasted upside of 342.8% from its current price of $6.71.Amount of Analyst CoverageVerastem has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.52% of the float of Verastem has been sold short.Short Interest Ratio / Days to CoverVerastem has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Verastem has recently decreased by 15.01%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVerastem does not currently pay a dividend.Dividend GrowthVerastem does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VSTM. Previous Next 2.2 News and Social Media Coverage News SentimentVerastem has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Verastem this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for VSTM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,565.00 in company stock.Percentage Held by InsidersOnly 2.90% of the stock of Verastem is held by insiders.Percentage Held by Institutions75.25% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Verastem are expected to grow in the coming year, from ($3.67) to ($3.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verastem is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verastem is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerastem has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Verastem Stock (NASDAQ:VSTM)Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of avutometinib and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.Read More VSTM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VSTM Stock News HeadlinesNovember 23, 2023 | americanbankingnews.comVerastem (NASDAQ:VSTM) Rating Reiterated by BTIG ResearchNovember 22, 2023 | finance.yahoo.comAll You Need to Know About Verastem (VSTM) Rating Upgrade to BuyNovember 30, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 22, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Bluebird Bio (BLUE) and Verastem (VSTM)November 15, 2023 | markets.businessinsider.comWhere Verastem Stands With AnalystsNovember 13, 2023 | finance.yahoo.comNew Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment ApproachNovember 12, 2023 | seekingalpha.comVerastem: Potential Accelerated Approval Filing In H1 2024November 11, 2023 | msn.comVerastem files $300M mixed securities shelfNovember 30, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 10, 2023 | markets.businessinsider.comPositive Outlook for Verastem: Accelerated Filing Plans, Financial Stability, and Upcoming Clinical Trials Underpin Buy RatingNovember 8, 2023 | finance.yahoo.comVerastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNovember 8, 2023 | markets.businessinsider.comVerastem: Promising Phase 2 Results and Upcoming Phase 3 Study Bolsters Buy RatingNovember 7, 2023 | finance.yahoo.comFirst-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian CancerNovember 6, 2023 | markets.businessinsider.comVerastem Reports Positive Data Of Avutometinib & Defactinib In Low-Grade Serous Ovarian CancerNovember 6, 2023 | finance.yahoo.comVerastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient PopulationOctober 28, 2023 | markets.businessinsider.comVerastem’s Strategic Executive Appointments and Potential FDA Approval Reinforce Buy RatingOctober 27, 2023 | benzinga.comVerastem Chief Financial Officer Awarded $162K Worth of Stock OptionsOctober 26, 2023 | finance.yahoo.comVerastem Oncology Strengthens Executive Leadership Team with Key AppointmentsOctober 25, 2023 | finance.yahoo.comVerastem Inc (2VS.BE)October 25, 2023 | money.usnews.comVerastem IncOctober 17, 2023 | markets.businessinsider.comPromising Potential for Verastem’s Stock with RAMP 203 Results: A Comprehensive Analysis and Buy RecommendationOctober 14, 2023 | finance.yahoo.comVerastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung CancerSeptember 30, 2023 | nasdaq.comB. Riley Securities Reiterates Verastem (VSTM) Buy RecommendationSeptember 28, 2023 | finance.yahoo.comVerastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development SummitSeptember 27, 2023 | markets.businessinsider.comAnalyst Ratings for VerastemSeptember 3, 2023 | msn.comWeek In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million DealAugust 28, 2023 | msn.comVerastem, China's GenFleet to collaborate on RAS pathway-driven cancer drugsSee More Headlines Receive VSTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today11/30/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/12/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:VSTM CUSIP92337C10 CIK1526119 Webwww.verastem.com Phone(781) 292-4200FaxN/AEmployees57Year FoundedN/APrice Target and Rating Average Stock Price Target$29.71 High Stock Price Target$36.00 Low Stock Price Target$21.00 Potential Upside/Downside+364.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.0408) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-73,810,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-115.85% Return on Assets-52.62% Debt Debt-to-Equity Ratio0.48 Current Ratio7.33 Quick Ratio7.33 Sales & Book Value Annual Sales$2.60 million Price / Sales62.20 Cash FlowN/A Price / Cash FlowN/A Book Value$3.29 per share Price / Book1.95Miscellaneous Outstanding Shares25,270,000Free Float24,534,000Market Cap$161.73 million OptionableOptionable Beta0.56 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Daniel W. Paterson (Age 62)President, CEO & Director Comp: $697.98kMr. Daniel Calkins (Age 36)CFO, Head of Investor Relations, Principal Accounting Officer & Financial Officer Comp: $310.67kMr. Richard H. Aldrich M.B.A. (Age 69)Founder and Consultant Comp: $38.39kDr. Robert A. Weinberg Ph.D.Co-Founder & Chair of Scientific Advisory BoardDr. Piyush B. Gupta Ph.D.Co-FounderDr. Michelle Dipp M.D. (Age 47)Ph.D., Co-Founder Mr. Robert Pintar M.B.A.Senior Vice President of Technical OperationsDr. Jonathan Pachter Ph.D. (Age 65)Chief Scientific Officer Comp: $238.18kMore ExecutivesKey CompetitorsXOMANASDAQ:XOMARigel PharmaceuticalsNASDAQ:RIGLMerrimack PharmaceuticalsNASDAQ:MACKVanda PharmaceuticalsNASDAQ:VNDAEmergent BioSolutionsNYSE:EBSView All CompetitorsInsiders & InstitutionsAdage Capital Partners GP L.L.C.Bought 700,000 shares on 11/15/2023Ownership: 5.144%Acuta Capital Partners LLCSold 70,000 shares on 11/15/2023Ownership: 0.910%Sectoral Asset Management Inc.Bought 203,327 shares on 11/15/2023Ownership: 0.805%Royal Bank of CanadaSold 56,810 shares on 11/15/2023Ownership: 0.168%Stifel Financial CorpSold 3,405 shares on 11/13/2023Ownership: 0.049%View All Insider TransactionsView All Institutional Transactions VSTM Stock Analysis - Frequently Asked Questions Should I buy or sell Verastem stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VSTM shares. View VSTM analyst ratings or view top-rated stocks. What is Verastem's stock price target for 2024? 7 Wall Street research analysts have issued 1 year price objectives for Verastem's stock. Their VSTM share price targets range from $21.00 to $36.00. On average, they predict the company's share price to reach $29.71 in the next year. This suggests a possible upside of 342.8% from the stock's current price. View analysts price targets for VSTM or view top-rated stocks among Wall Street analysts. How have VSTM shares performed in 2023? Verastem's stock was trading at $4.83 at the beginning of 2023. Since then, VSTM stock has increased by 38.9% and is now trading at $6.71. View the best growth stocks for 2023 here. When is Verastem's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024. View our VSTM earnings forecast. How were Verastem's earnings last quarter? Verastem, Inc. (NASDAQ:VSTM) announced its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.17. When did Verastem's stock split? Shares of Verastem reverse split before market open on Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is Robert Forrester's approval rating as Verastem's CEO? 11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Verastem own? Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX). Who are Verastem's major shareholders? Verastem's stock is owned by a number of institutional and retail investors. Top institutional investors include Adage Capital Partners GP L.L.C. (5.14%), Acuta Capital Partners LLC (0.91%), Vontobel Holding Ltd. (0.81%), Sectoral Asset Management Inc. (0.80%), Northern Trust Corp (0.18%) and Royal Bank of Canada (0.17%). Insiders that own company stock include Brian M Stuglik, Dan Paterson, Daniel Calkins, Robert E Gagnon and Timothy J Barberich. View institutional ownership trends. How do I buy shares of Verastem? Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:VSTM) was last updated on 11/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.